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Treatment of acute respiratory failure in the course of COVID-19. 
Practical hints from the expert panel of the Assembly of Intensive 
Care and Rehabilitation of the Polish Respiratory Society
Abstract
In 2019, a pandemic began due to infection with a novel coronavirus, SARS-CoV-2. In many cases, this coronavirus leads to the 
development of the COVID-19 disease. Lung damage in the course of this disease often leads to acute hypoxic respiratory failure 
and may eventually lead to acute respiratory distress syndrome (ARDS). Respiratory failure as a result of COVID-19 can develop 
very quickly and a small percent of those infected will die because of it. There is currently no treatment for COVID-19, therefore the 
key therapeutic intervention centers around the symptomatic treatment of respiratory failure. The main therapeutic goal is to main-
tain gas exchange, mainly oxygenation, at an appropriate level and prevent the intensification of changes in the lung parenchyma.
Depending on the severity of hypoxemia different techniques can be used to improve oxygenation. Medical staff dealing with 
COVID-19 patients should be familiar with both, methods used to treat respiratory failure and the epidemiological risks arising from 
their use. In some patients, conventional (passive) oxygen therapy alone is sufficient. In patients with worsening respiratory failure 
high flow nasal oxygen therapy (HFNOT) may be effective. The continuous positive airway pressure (CPAP) and non-invasive 
ventilation (NIV) methods can be used to a limited extent. With further disease progression, invasive ventilation must be used 
and in special situations, extracorporeal membrane oxygenation (ECMO) can also be administered.
The authors of this article set themselves the goal of presenting the most current knowledge about the epidemiology and patho-
physiology of respiratory failure in COVID-19, as well as the methods of its treatment. Given the dynamics of the developing 
pandemic, this is not an easy task as new scientific data is presented almost every day. However, we believe the knowledge 
contained in this study will help doctors care for patients with COVID-19. The main target audience of this study is not so much 
pneumonologists or intensivists who have extensive experience in the application of the techniques discussed here, but rather 
doctors of other specializations who must master new skills in order to help patients during the time of a pandemic.
Key words: acute respiratory failure, ventilatory support, non-invasive mechanical ventilation, high flow nasal oxygen therapy, 
COVID-19
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Introduction
The pandemic caused by the SARS-CoV-2 vi-
rus has, suddenly and unexpectedly, caused health 
services to be faced with previously unknown and 
difficult challenges. Since the main complication 
of this infection is severe viral pneumonia, pneu-
monologists and infectious disease specialists 
Advances in Respiratory Medicine 2020, vol. 88, no. 3, pages 245–266
246 www.journals.viamedica.pl
occupy a special place in the fight against this 
pandemic. At the turn of 2002–2003 a similar 
epidemic broke out, also due to the coronavirus, 
but only on a local scale ( Southeast Asia). Some 
infected patients developed severe pneumonia, 
which was characterized by a rapid clinical 
course and a high mortality rate due to acute 
respiratory failure. For this reason, this disease 
was called SARS, an acronym made from the first 
letters of the English name: severe acute respira-
tory syndrome. During that outbreak, there were 
8096 confirmed cases and 774 deaths, which sig-
nifies a high mortality rate of 9.5%. The epidemic 
at that time did not spread globally, and only 
single cases were reported in European countries 
[1]. In 2012 there was the second outbreak of ep-
idemic caused by coronavirus, which took place 
in Middle East and Northern Africa regions. Due 
to location it was called Middle East Respirato-
ry Syndrom (MERS). Till 2017 2040  cases and 
712 deaths was noted [2, 3].
As in 2002 and 2012, the cause of the current 
pandemic is the coronavirus, hence the name 
SARS-CoV-2. The receptor for this virus in the 
human body is the angiotensin II converting en-
zyme, whose significant expression is present in, 
among others, the respiratory epithelial cells [4]. 
That explains why the virus has a special affin-
ity for the lungs, among other organs. Since the 
world’s first reported incident of infection with 
the SARS-CoV-2 virus, the number of infected 
people has grown exponentially and has now ex-
ceeded eight million, of which over 465,000 have 
died. Infected patients have been found in every 
country of the world [5]. The massive number of 
seriously ill patients suddenly requiring medical 
attention shocked and overwhelmed the health 
care systems of even the richest countries, with 
painful examples being Italy, Spain, and the USA. 
Compared to other Western European countries, 
the pandemic reached Poland with some delay 
giving authorities and health care workers time 
to take preventive measures and learn from the 
experiences of other countries that first faced this 
pandemic. In this study, the authors, members of 
the Intensive Care and Rehabilitation Assembly of 
the Polish Respiratory Society (PTChP), present 
knowledge about the clinical picture as well as 
the methods of treating respiratory failure in the 
course of COVID-19.
Clinical picture of COVID-19
The main source of information about pa-
tients infected with SARS-CoV-2 comes from 
Chinese reports, with some recent input also 
coming from Italy and the USA. Guan et al. [6] 
retrospectively described 1099 hospitalized pa-
tients. Contrary to popular belief, which stated 
the severe course of the disease affects only el-
derly patients, the average age of this group was 
47 years old and almost 60% were men. Based 
on medical records, 173 patients (19%) were 
admitted in a severe condition. The risk factors 
for severe disease were advanced age and comor-
bidities. In the group of patients with a severe 
course, almost all patients (97%) had pathological 
changes in images produced by a CT scan of the 
chest on admission. Meanwhile, in the group of 
patients classified as having a mild course of the 
disease, only 19% had these changes. According 
to laboratory tests, severe patients had leukopenia 
and lymphocytopenia. 38% of severe patients re-
quired invasive ventilation, 15% required non-in-
vasive mechanical ventilation (NIV), and 8% died. 
Zhou et al. analyzed a group of 191 hospitalized 
patients. Of these patients, 54% had respiratory 
failure and 2/3 of them developed ARDS, which 
was fatal in most cases. Respiratory acidosis was 
a rare phenomenon and was found in only 9% of 
all patients [7]. In an analysis of 201 hospitalized 
patients by Wu et al. [8], 82% of patients required 
oxygen therapy, including almost half (49% of the 
entire group) requiring low-flow oxygen supple-
mentation through a nasal cannula. NIV was used 
in 30% of patients and 2.5% (5 patients) required 
intubation and invasive ventilation, including 
one patient who also needed extracorporeal blood 
oxygenation (ECMO). 53 patients (26%) required 
admission to the Intensive Care Unit (ICU), and 
44 (22%) died. Risk factors for death, as in previ-
ous studies, were older age, coexistence of chronic 
diseases, as well as neutrophilia and high levels of 
LDH and d-dimer on admission. According to the 
results of the analysis of 73,000 COVID-19 cases 
in China, 81% of patients had a mild disease, 
14% had a severe disease, and 5% had a critical 
disease. Mortality in this analysis was 2.3% [8] 
however, data on mortality vary from country to 
country. The highest rate of mortality (> 10%) 
was found in such countries as Italy, UK, and 
Belgium. One of the lowest rates was in Germany 
(< 1%) [9]. The mortality rate is most likely influ-
enced by various factors ranging from healthcare 
organizations (i.e. number of beds in the ICU) to 
reporting methods and death qualifications.
Here we will discuss a typical course of se-
vere COVID-19 [7]. The most commonly present-
ed symptoms on admission are increased body 
temperature and dry cough. The temperature 
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does not have to be high as it can be < 37.5°C. 
On admission, changes in the CT scan of the lungs 
may be present. After five to seven days, dyspnea 
appears, which increases in the following days 
or even hours and may be the reason for urgent 
intubation and invasive ventilation. Since the 
disease progression rate may vary, each patient 
should be monitored constantly with a special 
focus on  percutaneous measurement of the he-
moglobin oxygen saturation (SpO2).
An analysis of 1591 patients admitted to the 
ICU in Italy has recently been published [10] with 
82% being male. Therefore, the male sex could 
be considered a risk factor for the development 
of severe disease. The average age of this group 
was 63 years, with 2/3 of patients having at least 
one comorbidity, most often being hypertension. 
Interestingly, COPD was present in only 8% of 
patients over 70 years of age and was rarer in 
younger patients (3%). In contrast, co-existing 
COPD is associated with up to a five-fold greater 
risk of severe COVID-19 [11]. Doctors should be 
aware that severe respiratory failure and ARDS 
may also occur in young people without any 
co-existing diseases. In a group of 1300 patients 
described by Grasselli et al., data on the treatment 
of respiratory failure methods were presented. 
Almost everyone (98%) required ventilatory 
support; 1,150 (88%) patients needed invasive 
ventilation and only 137 (11%) were treated with 
NIV. 89% of patients required an oxygen supply 
with FiO2 greater than 50% [10]. Data from the 
USA indicates a lower percentage of necessary in-
tubation (71% of those treated in the ICU), but for 
now these are analyses of small groups of patients 
[12]. In China, the percentage of patients treated 
in the ICU and invasively ventilated ranged from 
30% to 47% [13, 14], while NIV treated patients 
ranged from 14% to 62%. The varied data regard-
ing the number of patients requiring invasive 
and non-invasive ventilation are probably due to 
different criteria for admission to the ICU, differ-
ent criteria for invasive ventilation, and differing 
availability of medical equipment.
Pathophysiology of respiratory failure in COVID-19
As the SARS-CoV-2 pandemic continues, we 
are able to learn more about the pathophysiologi-
cal aspects of COVID-19. The main complication 
of the severe course of this disease is viral pneu-
monia, which causes edema of the interstitium of 
the lungs, most often located in the sub-pleural 
areas. Therefore, CT scans of the chest reveal 
multifocal, diffuse, most often bilateral ground-
glass opacities. Despite the relatively small 
amount of lung parenchyma involved, severe 
hypoxemia may occur during this phase of the 
disease. The cause is not entirely clear, but most 
likely is due to a disturbance in the regulation 
of pulmonary vascular tone (vasoplegia), which 
does not constrict despite alveolar hypoxia. This 
causes a significant inadequacy in ventilation 
to perfusion ratio (V/Q mismatch). Since lung 
compliance is likely to be normal or only slight-
ly reduced with such small lesions, the patient 
usually has no difficulty increasing ventilation to 
improve PaO2, often leading to hypocapnia. Some 
Italian researchers describe this clinical picture 
(relatively small changes in chest imaging, nor-
mal lung compliance, and significant hypoxemia) 
as the disease’s “L” phenotype. This name comes 
from the first letter of the English terms for four 
characteristics: 1. Low elastance (high compli-
ance, normal or nearly normal in this case), 
2. Low V/Q ratio (low ventilation to perfusion 
ratio), 3. Low lung weight, and 4. Low lung re-
cruitability (weak effect of alveolar recruitment 
with positive airway pressure). The optimal 
form of treatment at this stage is passive oxygen 
therapy. At this stage, the disease may either go 
into the regression phase and towards recovery 
or into the progression of lung lesions towards 
ARDS. If the latter scenario takes place, the lung 
changes evolve into massive parenchymal infil-
trates covering large areas of the lung, a typical 
image of ARDS. This phenotype was named after 
the letter “H” from the first letter of English words 
describing the characteristic pathophysiological 
features: 1. High elastance (low compliance), 
2. High right-to-left shunt, 3. High lung weight, 
and 4. High lung recruitability (good response to 
the use of positive airway pressure in the form 
of alveolar recruitment and improved gas ex-
change). For phenotype H, the main mechanism 
of hypoxemia is right-to-left intrapulmonary 
shunt. Areas of the lung parenchyma involved in 
the inflammatory process are not ventilated while 
the perfusion is still ongoing, therefore, there 
is no gas exchange. Blood that perfuses these 
areas returns to the systemic circulation as still 
poorly oxygenated venous blood. The greater the 
amount of blood that flows through the affected 
(unventilated) lung parenchyma, the greater the 
hypoxemia. Figure 1 presents the mechanism of 
hypoxemia by way of right-to-left intrapulmo-
nary shunt. The use of positive airway pressure 
for ventilatory support (active oxygen therapy) 
is the treatment of choice in the H phenotype 
[15]. It is important to take into consideration 
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that prolonged strenuous respiratory effort may 
exacerbate (worsen) respiratory failure and cause 
a transition from “L” to “H” phenotype [15]. This 
phenomenon is called patient self-inflicted lung 
injury (P-SILI) and plays an important role in the 
pathophysiology of ARDS (caused not only by 
COVID-19). For this reason, ventilatory support 
(mechanical ventilation/CPAP/NIV) should not be 
delayed in patients with high respiratory effort. 
The described changes in lung parenchyma are 
presented in Figures 2 and 3.
In addition, hypercoagulability, which in-
creases the risk of thrombosis, is also a character-
istic of the severe course of COVID-19. Therefore, 
another mechanism by which hypoxemia can 
be caused and/or exacerbated is via pulmonary 
embolism. One report from a French center stated 
pulmonary embolism was found in 20% of 107 pa-
tients hospitalized in the ICU which, according to 
the authors, more than doubled the incidence of 
this complication among the general population 
of patients treated in the ICU [16].
Treatment of hypoxemia
Since there is no specific treatment for 
COVID-19, maintaining respiratory function 
by ensuring proper gas exchange and, above 
all, adequate oxygenation of blood is the most 
important therapeutic goal. Below, we will dis-
cuss methods of treating hypoxic respiratory 
failure starting with the simplest techniques 
allowing the use of a lower fraction of oxygen 
in inhalation gases (FiO2) all the way up to 
advanced techniques that allow the supply of 
high fraction of oxygen, even up to 100% under 
positive pressure. This does not mean that every 
patient should be started with a nasal cannula 
and all oxygen therapy techniques should be 
used in succession. On the contrary, depending 
on the patient’s initial state, severity of hypox-
emia, respiratory effort, available equipment, 
possibility of patient isolation, and the possi-
bility of implementing invasive ventilation, one 
should start with a treatment method that will 
ensure satisfactory oxygenation of blood while 
also taking the safety of the staff into account. 
Transcutaneous pulse oximetry should be used 
in the assessment of blood oxygenation due to 
its availability, ease of application, and possi-
bility of continuous measurement of this vital 
parameter. Assessment of the partial pressure of 
oxygen (PaO2) should only be used if there are 
doubts about the reliability of the SpO2 measure-
ment or if there is suspected hypercapnia. False 
SpO2 measurements may occur in the following 
clinical situations: improperly fitted sensor (not 
fully covering the distal phalanx), peripheral hy-
poperfusion, hypotension, arrhythmia, damaged 
distal phalanx, or if a patient has dark nail polish 
covering their fingernail. There is no consensus 
among scientific bodies regarding the optimal 
SpO2 value that should be achieved under the 
influence of treatment. The British Thoracic 
Society has recommended the SpO2 target to be 
between 94–98% since 2008 [17]. Currently, the 
WHO also recommends maintaining SpO2 > 94% 
in guidelines for the treatment of respiratory 
Figure 1. Schematic mechanism of hypoxemia (intrapulmonary shunt). On the left-hand side, a normal perfusion ventilation ratio can be seen, on the 
right-hand side, diseased lung area can be seen. In this area there is no ventilation, therefore no blood oxygenation may take place. In cases where 
the addition of non-oxygenated blood is large, the use of passive oxygen therapy will be probably ineffective, because the administered oxygen does 
not reduce intrapulmonary shunt, but only improves the oxygenation of blood passing through healthy pulmonary parenchyma
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failure in COVID-19 [18]. On the other hand, 
a panel of international experts in the field of 
intensive therapy draws attention to the harmful 
effects of hyperoxia (increased risk of death) and 
in a document issued in 2018, recommended 
maintaining SpO2 at 90–94% [19]. The Euro-
pean Intensive Care Society also recommends 
that SpO2 should not exceed 96% during the 
treatment of COVID-19 respiratory failure [20]. 
Regardless of which guidelines we adopt, treat-
ment should never allow for SpO2 to fall below 
90%. It seems that the target SpO2 should be be-
tween 92% and 96%. In the case of a patient with 
chronic hypercapnic respiratory failure, the rec-
ommendations are unambiguous. SpO2 should be 
maintained within 88–92% so as not to weaken 
the hypoxic respiratory drive and to not increase 
hypercapnia.
Conventional (passive) oxygen therapy 
Passive oxygen therapy refers to spontaneous 
breathing air with an increased oxygen content, 
which means a FiO2 within a range of 0.22 to 
1.0 (22% to 100%). This treatment can be per-
formed with the use of devices described below:
A. Nasal cannula
The nasal cannula is the simplest device 
for oxygen administration (Figure 4). The ox-
ygen fraction is titrated by changing oxygen 
flow through the cannula. Pure (100%) oxygen, 
which comes out of the cannula, is blended in 
the patient’s nostrils with the inhaled air to form 
a mixture of air and oxygen. This method does 
not allow for the administration of an inspiratory 
gas with a precise FiO2 value since it depends on 
A B
Figure 2. Picture of lung parenchyma involvement on the 4th day of treatment of 56-year-old woman infected with SARS-CoV-2. In chest ante-
rior-posterior radiograph (A) and high resolution computer tomography (B) areas of grand glass opacities, mainly with sub-pleural predominance. 
Respiratory insufficiency. Treatment with Venturi mask — FiO2 0.4 to be able to reach SpO2 94%
A B C
Figure 3. The course of COVID-19 in 37-year-old male in chest radiograph examinations. A. The admission day: disseminated parenchymal opa-
cities in both lungs. B. 5th day of hospitalization. C. 16th day of hospitalization. Visible gradual regression of the lesions. The patient with respiratory 
failure — required the use of oxygen with nasal cannula (flow 5 L/min). On day 16th the patient without hypoxemia
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the patient’s minute ventilation. The generally 
accepted FiO2 estimation method (an increase of 
4% with an increase in oxygen flow by 1 L/min) 
can be unreliable in patients with high respi-
ratory drive and high minute ventilation. It is 
believed that the flow should not exceed 6 L/min 
as a further increase in oxygen supply no longer 
significantly increases FiO2. For nasal cannula 
oxygen therapy, COVID-19 patients may be fitted 
with surgical  masks to minimize the risk of dis-
persion of aerosol.
B. Simple oxygen mask
A simple oxygen mask is a frequently used 
interface in general wards (Figure 5). Its advantage 
lies in the possibility to provide higher FiO2 [with-
in 0.4–0.6 (40–60%)] compared to oxygen therapy 
via a nasal cannula. However, its disadvantage 
is the lack of strict control of FiO2 administered 
and the risk of CO2 re-inhalation. To avoid this 
risk, oxygen flow should not be less than 5 L/min. 
The maximum flow is considered to be 10 L/min.
C. Venturi mask
If the nasal cannula or simple oxygen mask 
cannot provide adequate blood oxygenation, 
a Venturi mask can be used (Figure 6). The ad-
vantage of this mask is the ability to administer 
a mixture of air and oxygen with a constant and 
precisely selected oxygen fraction in the range 
of 24% to 60%. The FiO2 value is determined by 
selecting the appropriate sized port (Figure 7) and 
setting the appropriate oxygen flow assigned to 
the Venturi port. It should be remembered that the 
given oxygen flow rate is the minimum value that 
should be set. Therefore, it is not an error to set 
a higher flow rate when high minute ventilation 
is suspected. However, as the flow through the 
mask increases, the dispersion of exhaled gas in 
the room is also greater [21].
D. Non-rebreather mask
If oxygen therapy with a 60% Venturi mask is 
insufficient, a non-rebreather mask should be used 
(Figure 8). The principle mechanism of action of 
this mask is, with each breath, to inhale pure ox-
ygen from the reservoir attached to the mask. The 
one-way valve system prevents the exhaled and 
Figure 5. Oxygen therapy with the use of a simple oxygen maskFigure 4. Oxygen therapy with nasal cannula. Flow range should be 
titrated between 0.5 L/min and 6 L/min. This interface provides FiO2 
up to 0.4. Breathing with open mouth does not reduce FiO2 and is not 
a contraindication to use of nasal cannula
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inhaled air from mixing. In order for this treatment 
to be effective, the mask must be tightly fitted to 
the face so the patient does not breathe in air from 
the room and the oxygen reservoir must be filled 
promptly so the entire inspiratory volume comes 
from it. With correct use, it is possible to achieve 
a FiO2 of 0.8–0.95. The use of a non-rebreath-
er mask is the safest method to avoid medical 
personnel being infected because the expiratory 
aerosol is dispersed the smallest distance from 
the patient’s mouth, approximately 10 cm [22].
High-flow nasal oxygen therapy
A. Principle of operation
High-flow nasal oxygen therapy (HFNOT) re-
fers to administering high flow air (10–60 L/min.) 
enriched with oxygen at a concentration ranging 
from 22% to 100% through dedicated nasal prongs 
(Figure 9). In addition, the gas mixture is saturat-
ed with moisture and heated to a temperature of 
31–37°C, which closely mirrors the natural condi-
tions in the nasal cavity. Thanks to this, the patient 
tolerates high airflow very well. This would not be 
possible with dry, cool gas [23]. HFNOT is an in-
termediate method between passive and active ox-
ygen therapy. HFNOT has several beneficial effects 
on pathophysiology of respiratory failure. Firstly, 
high gas flow generates positive airway pressure 
(an increase in flow rate by 10 L/min results in an 
increase in airway pressure from 0.5–1.0 cmH2O), 
which increases functional residual capacity (FRC) 
and causes alveolar recruitments, enhancing gas 
exchange. Secondly, reduction of expiratory gases 
retention in the dead space. Thirdly, in patients 
with obstruction, high inspiratory flow and posi-
tive airway pressure reduce the work of breathing 
[24]. Figure 10 shows the HFNOT device and ex-
plains its principle of operation.
B. Scientific evidence
To date, no randomized clinical trials have 
been conducted to assess the effectiveness of 
HFNOT in the treatment of COVID-19 respiratory 
failure, but this method has been commonly used 
in China. A retrospective analysis of 610 patients 
commonly treated with HFNOT found a lower 
necessity for intubation and lower mortality rate 
compared to data from neighboring regions of 
China where HFNOT was not used [25]. Earlier 
observations during the influenza epidemic in 
2009 also pointed to the beneficial effects of HF-
NOT, although they were made on a small group 
of patients [26].
Figure 7. Venturi sized ports. In order to deliver certain FiO2 the 
adequate port has to be implemented between mask and cannula, and 
indicated oxygen flow rate has to be set up
Figure 6. Oxygen therapy with the use of Venturi mask. The red item is 
a Venturi sized port, where air and oxygen is blended to provide exact 
FiO2 between 24% and 60% Figure 8. Non-rebreather mask. Fully expanded reservoir bag, which 
contains pure oxygen, means effective oxygen flow in. This interface 
provides FiO2 at the level of 80–95%
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The randomized study assessing the ef-
fectiveness of HFNOT in the treatment of hy-
poxic respiratory failure showed a reduction 
in mortality in patients treated with HFNOT 
(PaO2/FiO2 < 300 mm Hg) compared to groups 
treated with conventional oxygen therapy (non-re-
breather mask) or NIV [27]. This study also found 
a reduction in the risk of intubation in a subset 
of patients with an oxygenation index (PaO2/FiO2) 
< 200 mm Hg. These observations became the 
basis for recommending HFNOT in the treatment 
of acute hypoxemia in COVID-19 in the first 
place, prior to the use of NIV. It is worth noting, 
this study did not include patients with chronic 
respiratory diseases and cardiogenic pulmonary 
edema (clinical situations in which NIV has prov-
en clinical efficacy). A meta-analysis of several 
randomized trials also confirmed that HFNOT 
reduces the risk of intubation [28] and the num-
ber of ICU admissions compared to conventional 
oxygen therapy [29]. These observations indicate 
that HFNOT can be used to treat hypoxic respira-
tory failure in COVID-19, especially where access 
to intensive care beds and ventilators is limited. 
WHO [18], the European Intensive Care Society 
[20], and numerous national scientific societies 
recommend this method.
C. Parameter titration
The optimal initial setting of gas flow (max-
imum or minimum) remains a matter of debate. 
Lower flow rates (35–40 L/min) are better toler-
ated [30], while a larger flow rate (40–60 L/min) 
achieves clinical benefits in a shorter time. These 
benefits include relieving shortness of breath, im-
proving oxygenation, and preventing inspiratory 
muscle fatigue [27]. In the case of a more severe 
clinical condition, you can start with a higher flow 
rate (e.g. 60 L/min) at the beginning to achieve 
rapid improvement and then titrate according to 
therapeutic goals and patient comfort [31]. Ini-
tial settings should be regularly adjusted to the 
patient’s current respiratory rate (so it reaches 
< 25–30 breaths/min), SpO2 (> 90%), and treat-
ment tolerance. If therapeutic goals are achieved, 
the flow rate should be reduced by 5–10 L/min 
every one to two hours. However, if the goals are 
not achieved, it is suggested to gradually increase 
the airflow rate by 5–10 L/min up to 60 L/min and 
then increase FiO2. If the patient’s clinical condi-
tion and SpO2 improve, we do the opposite by first 
lowering the FiO2 and then gradually reducing the 
amount of airflow by 5–10 L/min at a pace that is 
dependent on the patient’s clinical condition. If 
Figure 9. The interface for high-flow nasal cannula therapy
Figure 10. High-flow nasal cannula (HFNOT) device (AirVo2, Fish-
er&Paykel Healthcare, Auckland, New Zealand). A. High pressure 
oxygen circuit; B. High flowmeter (up 60 L/min); C. Oxygen cannula; 
D. Oxygen inlet with integreted blender and analyzer; E. Reservoir with 
distillated water supplied continuously (note the liquid bag on the top 
of rack), which serves as gas heater and humidifier; F. Inspiratory 
circuit leads the gas to nostrils
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the patient remains stable for one to two hours at 
an FiO2 ≤ 0.4 and airflow rate < 15 L/min, HFNOT 
can be discontinued and passive oxygen therapy 
can be started.
If the patient needs to be intubated, HFNOT 
can initially be used to improve oxygenation 
during laryngoscopy. In this case, the maximum 
flows and FiO2 (flow 60 L/min, FiO2 1.0) should 
be used [32, 33]. HFNOT has been shown to 
minimize adverse events such as desaturation 
severity, arrhythmias, and cardiac arrest during 
intubation [33].
Unfortunately, in the age of the SARS-CoV-2 
pandemic, the use of HFNOT may be associated 
with an increased risk of infection of medical 
personnel because during this process the ex-
haled air is dispersed in the form of aerosol drop-
lets. However, research has shown that the dis-
tance of dispersion is not great. With an airflow 
of 60 L/min, the distance is less than 20 cm [34]. 
During the 2003 epidemic with SARS-CoV-1, 
reports do not indicate that the use of HFNOT 
was a risk factor for personnel infection [35]. 
In order to minimize this risk, the latest German 
guidelines recommend putting surgical masks on 
the patient’s face [36].
Active oxygen therapy
If the use of passive oxygen therapy or HFNOT 
is ineffective and we do not achieve a SpO2 ≥ 90–
92% or if the patient’s respiratory effort is not re-
duced, active oxygen therapy should be initiated. 
It refers to the inhalation of inspiratory gases at 
a positive pressure (higher than atmospheric pres-
sure). Positive airway pressure may be delivered 
invasively by intubating the patient and starting 
mechanical ventilation or may be provided in 
a non-invasive manner through various types of 
interfaces (masks) applied to the patient’s face. 
The purpose of positive airway pressure is, among 
others, to recruit alveoli and increase the gas ex-
change area, as well as to prevent the occurrence 
of atelectasis in the lung parenchyma. The thera-
peutic effect is not always predictable and depends 
on the amount of pressure used and the nature 
and distribution of lung lesions. Positive airway 
pressure operation is demonstrated in Figure 11.
Figure 11. Schematic effect of the mechanism in which the positive airway pressure improves arterial blood oxygenation. The diagram on the left- 
-hand side illustrates the part of the pulmonary parenchyma that is involved in the disease (red color), due to the lack of ventilation in these areas, 
the ratio of ventilation (V) to perfusion (Q) is zero. This means that there is no gas exchange between the blood and the alveoli (intrapulmonary 
shunt). The diagram on the right-hand side shows the use of positive airway pressure, which increases the gas exchange surface (so-called alveolar 
recruitment) (blue) and improves the ventilation to perfusion ratio, thanks to which gas exchange occurs in some of the blood
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In most publications on the treatment of 
hypoxic respiratory failure, the authors use the 
common name for continuous positive airway 
pressure (CPAP) and describe it as non-invasive 
mechanical ventilation (NIV). This is justified by 
the fact that these patients require the application 
of positive airway pressure and not augmenting 
ventilation (i.e. bilevel positive airway pressure, 
BiPAP). However, from a physiological point of 
view, due to the fact that CPAP is not a method 
of ventilation in the literal sense, we will discuss 
both modes of non-invasive active oxygen therapy 
separately. CPAP will be understood as a mode of 
constant pressure and NIV understood as a mode 
of bi-level airway pressure (BiPAP).
A. Continuous positive airway pressure 
(CPAP)
The CPAP mode delivers gas into the respira-
tory system during inspiration and exhalation at 
a constant pressure higher than the atmospheric 
pressure. It is widely used in medicine, primar-
ily in the treatment of obstructive sleep apnea 
[37]. PEEP (positive end-expiratory pressure) 
refers to positive airway pressure at the end of 
exhalation in intubated patients and is used in 
intensive care in the treatment of ARDS [38]. The 
possibility of using CPAP in the treatment of re-
spiratory failure was already reported during the 
SARS-CoV-1 epidemic [39]. That being said, we 
do not have clinical trial results that allow us to 
provide clear guidelines on when and how to use 
CPAP in the treatment of patients infected with 
SARS-CoV-2. With this in mind, current clinical 
experience from doctors in Southern and Western 
Europe argue that this method can be effective in 
a certain group of patients. Constructed strategies 
for the treatment of COVID-19 also suggest taking 
this method into account [40], especially in pa-
tients without hypoventilation, which is typical 
for patients with COVID-19.
The advantages of CPAP therapy include high 
availability, low cost, no need to have high medi-
cal competence when using it, no patient-device 
asynchrony (possible when using ventilation), 
high safety of treatment, and the possibility 
of using the patient’s own CPAP device (if the 
patient uses this method in treatment of sleep 
apnea). It should also be noted that the use of 
CPAP in improving oxygenation might be even 
more effective than when using NIV, as the mean 
respiratory pressure value during ventilation 
with bilevel positive airway pressure (BiPAP) is 
usually lower than the CPAP values, which are 
significantly higher. Moreover, a lack of increase 
in inspiratory volume through the use of CPAP, 
as opposed to NIV, may have additional signifi-
cance in the treatment of this group of patients as 
it is part of the strategy of protecting lungs from 
overdistension (volutrauma and barotrauma) [41].
Indications for CPAP 
(non-invasive CPAP therapy)
We do not have clear guidelines based on 
strong scientific evidence determining the criteria 
for CPAP treatment. This therapy should be con-
sidered when passive oxygen therapy or HFNOT 
is ineffective and should be undertaken before 
invasive ventilation is started if the patient’s 
status allows for this. A consultant intensivist 
makes this decision. The main purpose of using 
CPAP is to protect the patient against the need for 
intubation. The guidelines proposed by various 
scientific societies are based mainly on reports 
from regions with the most experience in the 
treatment of the COVID-19 disease. Decisions to 
initiate or discontinue this form of therapy should 
be taken individually and must take into account 
the following aspects:
1. Patient’s condition (risk of intubation);
2. Planned escalation of therapy (whether the 
patient would be qualified for invasive ven-
tilation if his condition worsens or not);
3. Availability of medical equipment (i.e. CPAP 
devices, masks);
4. Experience of medical staff in its application;
5. Options for protecting medical staff against 
infection.
The British Thoracic Society (BTS) suggests 
starting CPAP therapy if the significant respira-
tory effort and respiratory rate ≥ 20 min persists 
and when, despite passive oxygen therapy with 
FiO2 ≥ 0.4, SpO2 is below 94% [42]. In addition, 
the coexistence of obstructive sleep breathing 
disorders (it is worth considering unrecognized 
obstructive sleep apnea, especially in obese 
patients) may be an additional indication for 
early use of CPAP in patients hospitalized due 
to COVID-19.
How to use CPAP therapy in the treatment 
of COVID-19?
Interfaces. When choosing the type of inter-
face, take into consideration both the possibility 
of conducting effective therapy as well as the 
safety of medical personnel. The characteristics 
of individual types of interfaces are presented in 
Table 1. Given this information and considering 
the quick and vast spread of the disease, as well 
as the danger that it poses, it seems the most 
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optimal type of interface is a helmet. Despite the 
lack of hard scientific evidence, it is believed that 
it has the smallest risk of infection, due to the 
fact that the patient breathes in a closed space 
under the helmet and the air escaping from the 
helmet passes through a filter (Figure 12) [43]. In 
addition, the helmet is the best fitting interface 
available thanks to the flexible, cuffed collar 
Figure 12. Non-invasive ventilation with the use of helmet and double limb respiratory circuit. On the left-hand side inspiratory arm of the circuit 
comes to the helmet (black arrow), on the right-hand side expiratory arm with antiviral filter (empty arrow)
Table 1. Comparison of interfaces used in conducting non-invasive active oxygen therapy (CPAP or bi-level PAP)
Helmet Nasal mask Oral-nasal mask Full face mask
Unintentional 
leakage
Generally absent when 
the collar is inflated 
around the neck
Frequently excessive 
due to breathing through the 
open mouth
It is common 
but manageable 
in most patients




on patients face 
with prolonged use
Are not present They are very common 
on the nose bridge
They occur in almost all 
patients on nasal bridge
Very rarely
The possibility of 
using high pressures
Unlimited Usually poor tolerance 
and very large leaks
Often poor tolerance 
and large leaks
Often poor tolerance due 
to very large leaks
Ease to use by staff Dedicated to handle 
by training 
and experienced staff
Relatively simple Relatively simple Relatively simple
Communication 




Normal, the patient 
can communicate
Limited Limited
Fluid oral intake Possible through 
a special channel 
dedicated to carry 
the fluid probe
Convenient Requires mask removal Requires mask removal
Advances in Respiratory Medicine 2020, vol. 88, no. 3, pages 245–266
256 www.journals.viamedica.pl
around the neck, which further reduces the risk 
of spraying aerosol droplets containing the vi-
rus. The helmet perfectly controls leaks in spite 
of a high pressure under it, which is extremely 
important in terms of effective treatment. An-
other advantage of the helmet is the possibility 
of long-term treatment. Since the helmet is not 
leaning on any part of the face, there are no 
pressure sores on the skin. However, an import-
ant side effect is the noise generated by the air 
flowing inside the helmet. It is recommended 
for the patient to wear earplugs when using this 
interface. In addition, a complication that may 
occur is swelling of the upper limbs, due to the 
pressure created by the belts supporting the hel-
met, which pass under the armpits. The solution 
to this problem is to attach straps to the harness 
on the patient’s hips.
The second best option is to use a full-face or 
oral-nasal mask. Nasal masks are not applicable 
in the treatment of patients with severe shortness 
of breath. These patients breathe through their 
open mouths, which causes large leaks and an 
inability to maintain therapeutic pressure, thus 
exposing staff to infection. When using a mask 
with ventilator, the respiratory circuit should be 
composed in such a way that the patient exhales 
through the antiviral filter. Therefore, masks 
with a leak port located in the mask itself should 
not be used and we instead recommend using 
non-vented masks (without an exhalation port). 
There are three variants of respiratory circuits 
with non-vented masks:
1. A double-limb (Figure 13);
2. A single-limb with an exhalation valve (Figure 14);
3. A single-limb with a leakage port (whisper 
swivel type) located in the distal part of the 
circuit before the filter (Figure 15).
CPAP devices
CPAP therapy may be provided be several 
various types of devices:
Ventilator. The optimal device for the use of 
CPAP in a patient with hypoxic respiratory failure 
is a ventilator, which allows for the titration of 
FiO2 up to 100%. It is particularly advantageous to 
use a ventilator when applying positive pressure 
with an interface that has a large dead space (espe-
cially a helmet) because a large airflow is required, 
which simpler devices may not be able to generate.
CPAP machine. The most commonly used 
positive airway pressure generator is a CPAP de-
vice dedicated for home use. The problem with 
these devices lies in generating a gas mixture with 
FiO2 greater than 0.4. If a high FiO2 is needed, the 
oxygen supply to the respiratory circuit should be 
increased. To this end, pressure regulators with 
a flow greater than 15 L/min should be available. 
A device that generates a constant pressure of no 
less than 20 cmH2O is needed to use the helmet, 
so most home CPAP devices cannot be used with 
this interface.
CPAP valve mask. The pressure generator 
can be the flow of blended oxygen and air itself. 
A device called the Venturi Flow Generator/Driv-
er, guarantees a sufficiently high flow (at least 
40 L/min) in order to achieve the correct airway 
pressure level. The level of FiO2 is regulated by 
a Venturi port and properly selected oxygen and 
airflow. Whereas, the CPAP level is generated by 
the exhalation valve (Figure 16).
The Boussignac CPAP valve system (Vygon, 
Ecouen, France), used the Bernoulli principle with 
a virtual valve effect [44], is the only commercial-
ly available device that does not incorporate an 
air-entrainment Venturi system. It is composed of 
a CPAP mask connected to a cylindrical plastic 
tube (Figure 17). Gas from an oxygen source flows 
through the four parallel micro-channels within 
the tube independently, creating turbulent gas 
flow and positive pressure within the hollow cyl-
inder. The performance of the Boussignac CPAP 
system depends only on the delivered oxygen 
flow [45]. FiO2 and positive pressure cannot be 
set by the operator because both are a result of the 
oxygen flow setting required to power the device 
and the amount of air the patient inhales above 
that delivered by the device.
CPAP valve helmet. Bearing in mind a high 
degree of security of helmet in COVID-19 therapy 
Figure 13. Double limb respiratory circuit for non-invasive ventilation 
or CPAP consist of inspiratory and expiratory limb. Note the non-ven-
ted mask and the antiviral filter (empty arrow) between the mask 
and the circuit
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it is practical to consider to use continuous-flow 
CPAP generator with helmet with exhalatory 
valve. These are Venturi-effect flow generators, 
capable of delivering high flows up to 180 L/min 
and to adjust FiO2 from 30% to 100%. An easy to 
use device even outside intensive care (ex. pneu-
mology, internal medicine). For a proper CPAP 
therapy with the helmet, flows of air/oxygen of 
at least 40–50 L/min are needed. It can be used 
with all models of both helmets and masks for 
CPAP therapy. Continuous-flow CPAP generator 
with helmet with exhalatory valve is widely used 
in Italy.
CPAP technical aspects
Pressure titration. The CPAP level deter-
mines the effectiveness of improving blood oxy-
genation. It is recommended to start using CPAP 
with pressures of 10–12 cmH2O and gradually 
increasing them to 20 cmH2O depending on 
how the patient tolerates treatment, leaks, and 
SpO2. In an Italian study evaluating the treatment 
of 1,300 patients in the ICU, the average CPAP 
level was 14 cmH2O, while the maximum was 
22 cmH2O [10].
Humidification. Humidification of inhaled 
gases is not recommended because of the in-
creased risk of aerosol spread [46].
Treatment time. The efficacy of CPAP therapy 
should be strictly monitored so there is no delay 
in escalating therapy to invasive ventilation if 
needed. The principles of patient monitoring 
should be based primarily on the analysis of the 
oxygenation index (PaO2/FiO2 or SpO2/FiO2) and 
evaluation of clinical parameters (i.e. respiratory 
rate, degree of shortness of breath, and level of 
consciousness). The assessment of these param-
eters should be carried out in the initial period 
of therapy (1–2 hours) constantly. If continuous 
monitoring of the patient is not possible, satis-
factory efficacy and tolerance must be proven 
30 minutes after commencement of CPAP therapy, 
during which time it should be used constantly 
to achieve clinical improvement.
Conducting CPAP treatment in prone po-
sition may have additional benefits in terms of 
Figure 14. Non-invasive ventilation with the use of non-vented full face 
mask and single limb respiratory circuit with expiratory valve. The expi-
ratory valve (black arrow) opens only during expiration.  Note the an-
tiviral filter (empty arrow) between the mask and the expiratory valve
Figure 15. Non-invasive ventilation with the use of non-vented full 
face mask and single limb respiratory circuit with leak port. Note the 
leak port (black arrow) and antiviral filter (empty arrow) between the 
mask and the leak port
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improved oxygenation. The authors found only 
one prospective study assessing the effectiveness 
of such therapy in a small group of 20 patients 
with moderate or severe ARDS in the course of 
viral pneumonia. Therapy in the prone position 
was carried out for two hours per day [47]. The 
results of this innovative study do not provide 
definitive conclusions about the effectiveness 
of this positioning, however, there are more and 
more studies on prone positioning in nonitubated 
patients with COVID-19 , especially from France 
[48] and Italy [49], stating that pO2 is higher in 
the prone position rather than supine.
B. Non-invasive ventilation (NIV)
Treatment of de-novo acute 
respiratory failure
Non-invasive mechanical ventilation (NIV) 
is not the treatment of choice for acute (hy-
poxemic) respiratory failure (ARF, so called 
de-novo ARF) that occurs in most patients with 
COVID-19. De-novo ARF is defined as acute respi-
ratory failure in a patient without chronic respira-
tory diseases characterized by severe hypoxemia 
(oxygenation index: PaO2/FiO2 ≤ 200–300 mm Hg). 
The most common causes of ARF are pneumonia 
or ARDS. There are a number of exceptional sit-
uations in which the use of NIV in ARF has been 
demonstrated to have a beneficial effect [50]:
1. ARF in an immunocompromised patient;
2. ARF as a post-operative complication;
3. ARF as a consequence of cardiogenic pulmo-
nary edema;
4. ARF due to chest trauma.
The purpose of NIV in ARF is to improve 
blood oxygenation, facilitate ventilation, reduce 
respiratory effort, and prevent intubation and 
complications associated with invasive ven-
tilation. In 2012, a pilot study was published 
on a small group of 40 patients with moderate 
hypoxemia (PaO2/FiO2 in the 200–300 mm Hg 
range) who were randomized to NIV or high-flow 
oxygen therapy via a Venturi mask. A significant 
reduction in the number of intubations was 
found (1 patient in the NIV group and 7 patients 
in the oxygen therapy group, p = 0.04) as well 
as a positive trend towards lower mortality [51]. 
Unfortunately, this promising study was not re-
peated in a larger group of patients. Individual 
observational studies conducted in specialized 
intensive care centers also pointed to the pos-
sibility of beneficial effects of NIV in selected 
patients. However, the percentage of patients with 
NIV failure reached 50% in the case of pneumonia 
and ARDS [52, 53]. The reason for the frequent 
failure of NIV in the treatment of ARF can be 
explained by several factors:
1. Difficulty with controlling unintentional leaks;
2. The need to take breaks in conducting NIV 
due to individual variability in tolerance;
3. The possibility of stomach distension, which 
can significantly impair ventilation;
Figure 17. Boussignac CPAP system. The three components of the 
system includes: A. face mask; B. the Boussignac CPAP valve; C. oxy-
gen tubing [68]
Figure 16. CPAP therapy with the use of Venturi Flow Generator (Easy 
Flow Venturi). Air and oxygen are delivered via separate cannulas to 
Venturi adjustable port (white arrow). The valve in the mask (empty ar-
row) generates positive pressure under the mask which can be titrated
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4. Difficulty in providing protective ventilation 
(small tidal volumes of approx. 6 mL/kg of 
predicted body weight) [54], especially in 
patients with a higher respiratory drive gener-
ating high transpulmonary pressures leading 
to ventilator-induced lung injury (VILI);
5. The inability to deeply sedate the patient in 
case of significant patient-ventilator asyn-
chrony;
6. Difficulty in providing NIV in the prone 
position, which is beneficial in improving 
oxygenation in patients with ARDS [55], al-
though some attempts have been made [47];
7. An inability to paralyze the patient’s mus-
cles, which would be beneficial in not only 
facilitating protective ventilation, but also 
improving the redistribution of blood from 
skeletal muscles to internal organs [56].
The main concern with regards to the treat-
ment of patients with ARF with NIV is the potential 
delay of intubation and invasive ventilation. NIV 
failure is a predictive factor of higher mortality 
and complications associated with invasive ven-
tilation. Risk factors for NIV failure include [53]:
1. Severe state of the patient, expressed by a 
high SAPS II score (Simplified Acute Physi-
ology Score II) > 35 points;
2. > 40 years old;
3. Severe ARDS, PaO2/FiO2 < 100 mm Hg;
4. No improvement during the first hour of NIV, 
expressed as an oxygenation index of < 146 
mm Hg after 1 hour.
NIV was used during the SARS epidemic in 
2002 and during the swine flu virus epidemic in 
2009. In the first case, the failure rate was about 
30% [57], while in the second, it was highly 
variable and ranged from 13 to 77% [58]. Due 
to the lack of controlled studies about whether 
or not the use of NIV reduces the risk of intuba-
tion and death due to ARF in the course of viral 
pneumonia, the European Respiratory Society 
issued guidelines in 2017 in which they abstained 
from taking a position on the appropriateness 
of using NIV in such situations [59]. The use 
of BPAP should be considered in patients who 
cannot tolerate the administration of CPAP due 
to discomfort on expiration. The amount of pres-
sure support should not markedly increase the 
tidal volume so as not to intensify the potential 
damaging effect on the lungs. It is believed that 
an inspiratory pressure 4–10 cmH2O higher than 
the expiratory pressure should effectively com-
pensate for the effect of expiratory resistance 
while not generating large pressure differences 
during the breathing cycle. In summary, NIV can 
be conducted in the case of ARF when it presents 
with a mild or moderate hypoxemia, preferably 
in a center with experience in conducting this 
form of ventilatory support. This center should 
also be able to ensure constant monitoring of 
the patient with urgent access to intubation and 
invasive ventilation
Treatment of an acute-on-chronic 
respiratory failure
In the case of a patient with COVID-19 also 
suffering from an acute exacerbation of chronic 
respiratory failure associated with hypercapnia 
(i.e. an exacerbation of COPD), the indications 
for the use of NIV are the same as for an acute 
exacerbation of COPD caused by any other dif-
ferent etiology. In such a clinical situation, the 
benefits of non-invasive ventilatory support are 
well documented and proven to reduce the risk 
of intubation, death, and complications associ-
ated with invasive ventilation [50]. Respiratory 
acidosis (pH < 7.35) is an indication for starting 
NIV. However, patients with chronic respiratory 
failure and COVID-19 may develop more severe 
hypoxemia, which could significantly reduce the 
efficacy of NIV.
Monitoring of patients in non-ICU setting
The monitoring of every patient with 
COVID-19 is necessary for their proper manage-
ment due to the potential risk of acute respiratory 
failure. In 2017 the British authors created the 
‘National Early Warning Score 2’ (NEWS2) which 
can be helpful in monitoring patients at risk of 
respiratory failure [60]. It is simple to fill out 
and can be completed by lower qualified medi-
cal personnel (i.e. medical or nursing student). 
NEWS2 consists of information about vital signs, 
state of consciousness, and facts about their use 
of oxygen therapy. Each measurement value is 
converted into points, the sum of which indi-
cates the type of intervention to be undertaken. 
The greater the sum of points, the more severe 
the patient’s condition and the more frequent 
subsequent assessments that a patient requires.
In patients with severe respiratory failure 
requiring oxygen therapy with a high FiO2 > 0.4, 
or treated with HFNOT or NIV, continuous moni-
toring of vital signs, especially SpO2 and respira-
tory rate, should be required. This is because the 
patient’s potential sudden deterioration will be 
an indication for intensified treatment (intubation 
and invasive ventilation), as long as there is no 
Do Not Resuscitate (DNR) order. 
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Figure 18. Algorithms for the treatment of respiratory failure in COVID-19 in general ward with the use of conventional of oxygen therapy
In 2016, Roca et al. created an index with the 
acronym ROX to predict the success of HFNOT 
in patients with acute respiratory failure due to 
pneumonia [61]. The ROX index combines three 
common measurements: FiO2, SpO2, and respi-
ratory rate.





For example, in a patient with a respiratory 
rate of 30/min and SpO2 of 90%, with FiO2 set at 
0.50, the ROX index is 1.5. This index is based 
on the assessment of two elements in the func-
tioning of the respiratory system which, on one 
hand, are simple to measure, and on the other, 
reflect its functioning very well. These are respi-
ratory rate, which reflects respiratory effort and 
the SpO2/FiO2 ratio, which highlights the degree 
of impairment of gas exchange. Higher oxygen 
concentrations necessary to maintain an adequate 
SpO2 and a higher respiratory rate are evidence of 
a greater impairment of respiratory function and 
thus a higher risk of failure of HFNOT. Among 
the components of this index, SpO2/FiO2 had 
a greater value than the respiratory rate. These 
observations confirm the importance of using the 
right amount of FiO2 in increasing the chance of 
success with HFNOT [62]. The prognostic value of 
the ROX index was verified during a multicentre, 
prospective study involving 191 patients with 
pneumonia [63]. This study showed that ROX 
≥ 4.88 after 2, 6, or 12 hours of HFNOT indicat-
ed success. While values ​≤ 2.85 after 2 hours, 
≤ 3.47 after 6 hours, and ≤ 3.85 after 12 hours of 
using HFNOT testified to its inefficacy. It should 
be remembered that the reliability of the ROX 
index has not yet been assessed in patients with 
 COVID-19. In 2019, the monitoring and man-
agement algorithm for using HFNOT for acute 
hypoxemic respiratory failure was updated [31] 
and took into account the ROX index and the 
latest reports on prognostic index values [33].
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Algorithms for the treatment of respiratory 
failure in COVID-19 outside of the ICU are shown 
in Figures 18 and 19.
Invasive ventilation
In situations where the above-mentioned 
methods of treatment of respiratory failure prove 
to be ineffective, indications for invasive ven-
tilation should be established after anesthesia 
consultation. These indications include:
1. From a clinical point of view: significant 
respiratory effort with signs of inspiratory 
muscle fatigue and failure of other organs 
and systems — cardiologic, hemodynamic, 
and disorders of consciousness; 
2. From a pathophysiological point of view: 
severe hypoxemia and/or severe hypercapnia 
with or without respiratory acidosis that is 
not improving or is worsening despite inten-
sive treatment.
In the course of the SARS-CoV-2 infection, 
ARDS may develop. It is not a primary lung 
disease but a type of extensive inflammatory 
process in the lungs stemming from various 
etiologies. ARDS in the course of COVID-19 of-
ten develops rapidly and unpredictably. From 
a practical point of view, it is important to know 
the criteria for the diagnosis and classification of 
ARDS, as well as the general principles of ARDS 
treatment associated with the use of invasive 
ventilation.
In 2012, an international group of experts 
established a new definition called the “Berlin 
definition” [64]. This re-organized definition 
was made in order to facilitate a more accurate 
diagnosis of ARDS and to allow for a better ad-
aptation of therapeutic management linked to 
the severity of this syndrome, both in clinical 
trials and in everyday practice. It was agreed that 
ARDS is a type of sudden injury due to inflam-
matory factors acting on the lungs, which leads 
Figure 19. Algorithms for the treatment of respiratory failure in COVID-19 with the use of conventional and advanced technics of oxygen therapy 
(HFNOT, CPAP, NIV)
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to increased pulmonary vascular permeability, 
and loss of lung parenchyma. Markers of this 
clinical syndrome are severe hypoxemia, bilat-
eral parenchymal lung lesions corresponding to 
non-cardiogenic pulmonary edema (in standard 
chest radiography or computed tomography), and 
pathophysiological disorders such as right-to-left 
shunt, increased dead space, and decreased lung 
compliance. There are four criteria necessary for 
the diagnosis of ARDS:
1. Time criteria: the appearance of new or wors-
ening existing respiratory symptoms within 
1 week;
2. Radiological criteria: bilateral parenchymal 
infiltrates that are not caused by exudate, 
atelectasis, or tumor;
3. Causal criteria: respiratory failure not due to 
heart failure or fluid overload; an objective 
assessment (i.e. echocardiography) is re-
quired in order to exclude hydrostatic edema 
if ARDS risk factors are not present;
4. Gasometric criteria: forms the basis for clas-
sifying severity of ARDS.
The basis for this classification is based on 
the oxygenation index (i.e. the ratio of PaO2 to 
FiO2). In this regard, there is:
 — mild ARDS: 200 mm Hg < PaO2/FiO2 ≤ 
300 mm Hg with PEEP/CPAP ≥ 5 cmH2O;
 — moderate ARDS: 100 mm Hg < PaO2/ 
/FiO2 ≤ 200 mm Hg with PEEP ≥ 5 cmH2O;
 — severe ARDS: PaO2/FiO2 ≤ 100 mm Hg 
with PEEP ≥ 5 cmH2O.
The three above-mentioned categories of 
mild, moderate, and severe ARDS were created to 
ensure risk stratification and improve the choice 
of treatment method and setting. At the same time, 
the widely used term “acute lung injury” (ALI) 
has been removed from the definition of ARDS. In 
the new classification, each ARDS category (mild, 
moderate, severe) is defined by mutually exclusive 
ranges of PaO2/FiO2 values. The creation of a mild 
category of ARDS formalizes what was previously 
seen as a less severe form of the syndrome. Finally, 
by introducing the term mild ARDS, the severity 
of the disease (27% mortality) and response to 
protective lung ventilation were recognized. 
Over the past 20 years, many clinical studies 
have been conducted with the goal of develop-
ing an optimal treatment for ARDS [65]. Most of 
them were performed by a group of researchers 
associated with the ARDS-Network. The AR-
DS-Network protocol, referred to as the Lung 
Protective Strategy, should be implemented into 
standardized practice for the treatment of ARDS 
in intensive care units. Of the several test modes 
of rescue ventilation in ARDS [high PEEP venti-
lation, recruitment maneuvers, prone position, 
inverse ratio ventilation (IRV), airway pressure 
release ventilation (APRV), and high frequency 
oscillation (HFO)], only prone position proved 
to be a method that improved ventilation with 
scientifically documented significance. The use of 
neuromuscular blockade has also been shown to 
be an important aspect of improving the effective-
ness of ventilation in severe ARDS, but remains 
controversial [56]. From the evaluated rescue 
therapies in ARDS (surfactant, NO inhalation, 
extracorporeal CO2 removal, and extracorporeal 
oxygenation), only extracorporeal membrane ox-
ygenation (ECMO) proved to be therapeutically 
valuable in the treatment of ARDS, although the 
effectiveness of most these techniques were not 
evaluated in controlled studies in acute respira-
tory failure in COVID-19.
Extracorporeal gas exchange support
Extracorporeal gas exchange support is the 
most advanced alternative method to mechanical 
ventilation in terms of respiratory support. Its 
task is to replace gas exchange in the lungs while 
they recover. It consists of two techniques: extra-
corporeal membrane oxygenation (ECMO) and 
extracorporeal carbon dioxide removal (ECCO2R). 
The ECCO2R device is a variant of ECMO char-
acterized by low blood flow and reduced blood 
oxygenation with a less invasive technique that 
uses much smaller vascular cannulas. Extracor-
poreal oxygenation of blood involves the use of 
a modified extracorporeal circulation apparatus, 
which is intended for long-term use. There are 
two types of ECMO:
1. Veno-arterial ECMO: replaces the work of the 
heart and lungs and is used in the most severe 
circulatory-respiratory distress syndromes 
because, apart from blood oxygenation, it 
generates mechanical circulatory support;
2. Veno-venous ECMO: supports the work of 
the lungs and is used in respiratory failure.
Currently, the role of this method in support-
ing respiration was established after the publica-
tion of the results of the CESAR study in 2009 and 
EOLIA study in 2017, which state that ECMO 
can be considered an effective rescue method 
for patients who did not benefit from the use 
of optimal invasive ventilation (prone position, 
neuromuscular blockade, and use of high PEEP).
In Poland, the detailed recommendations 
and guidelines of the ECMO Venous Therapy 
Team were developed in the form of a protocol 
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and published in its original form in 2009 and 
then updated in 2016 [66]. These indications 
apply in full to the use of ECMO in the SARS-
CoV-2 pandemic. In practice, a pneumonologist 
should generally consider the possibility of using 
veno-venous ECMO in two clinical situations:
1. A severe form of acute respiratory failure 
when gas exchange cannot be provided by 
conventional mechanical ventilation and 
respiratory failure is potentially reversible;
2. Theoretically, as a bridge for lung transplan-
tation patients with end-stage respiratory 
failure [67].
According to Polish guidelines, the most im-
portant contraindication to ECMO therapy is the 
irreversibility of the disease. In addition, other 
contraindications for this method of treatment 
include: severe systemic disease, immunosuppres-
sion, intracranial hemorrhage, contraindications 
to anticoagulation therapy, invasive ventilation for 
over 7–10 days, lack of treatment with a respirator 
according to the Lung Protective Strategy, lack of 
consent of the patient, and over 65 years of age. 
ECMO therapy should be discontinued when there 
is extensive ischemia of the brain, massive intra-
cranial bleeding, a diagnosis of another incurable 
disease, and in the absence of improvement of 
respiratory function despite therapy [66].
Summary
The COVID-19 disease is mild in approx. 
80% of cases, but other patients require hospi-
talization and a large proportion of them develop 
viral pneumonia. The consequence of this is 
acute hypoxic respiratory failure. In the SARS-
CoV-2 pandemic era, knowledge of how to treat 
respiratory failure is important. All physicians 
should have this knowledge because treating 
patients with COVID-19 may be the responsibility 
of not only specialists in respiratory or intensive 
care medicine, but also the responsibility of 
doctors who do not deal with the treatment of 
respiratory failure in their daily practice. There-
fore, the main target audience of this review are 
not so much pulmonologists who have extensive 
experience in applying the techniques discussed 
here, but rather doctors of other specialties, who 
in the age of pandemics must master new skills.
In the absence of specific and causal treat-
ments for COVID-19, the primary therapeutic task 
is symptomatic management, which consists of 
ensuring adequate oxygenation of the blood. The 
optimal SpO2 value that should be maintained is 
considered to be between 92–96%. The first step 
in the treatment of hypoxic respiratory failure is 
oxygen therapy. It can be guided by the  following 
methods: nasal cannula, simple oxygen mask, 
Venturi mask, or a non-rebreather mask. Choos-
ing the right technique depends primarily on the 
effectiveness of obtaining adequate oxygenation, 
and secondly, on the patient’s tolerance of the 
treatment. If treatment with oxygen therapy is 
ineffective, high-flow nasal oxygen therapy can be 
used. This is a relatively new treatment method, 
which due to its simple technique and high effi-
ciency, is increasingly used in clinical practice. 
It is more effective than conventional oxygen 
therapy because it improves SpO2 and reduces 
respiratory effort. Its advantage over passive oxy-
gen therapy is that, apart from the supply of a gas 
mixture with a high (up to 100%) oxygen content, 
it also generates a low positive airway pressure. 
Thanks to this, it is considered a method that is 
in-between passive and active oxygen therapy. 
Active oxygen therapy refers to administration of 
inspiratory gases with positive airway pressure. 
This results in improved gas exchange in the al-
veolar recruitment mechanism. Oxygen therapy 
methods using positive airway pressure include 
CPAP and non-invasive mechanical ventilation 
(BiPAP). Considering the risk of personnel being 
infected by aerosol droplets from the patient’s ex-
haled air, the best interface for using CPAP/BiPAP 
is a helmet or face mask. Since these interfaces 
are unvented, they do not allow the exhaled air 
to spread directly into the room without passing 
through the filter.
Patients with mild respiratory failure can be 
hospitalized without constant monitoring. The 
NEWS2 scale is recommended to assess their con-
dition. In the event of moderate or severe hypox-
emia, vital signs, including primarily SpO2 and 
respiratory rate, must be monitored continuously. 
These patients should be placed in a high de-
pendency unit. The main purpose of monitoring 
is to control the effectiveness of treatment by 
maintaining adequate SpO2, reducing shortness 
of breath and breathing effort. In the absence of 
improvement during the first two hours of treat-
ment, consideration should be given to admit 
the patient to the ICU because of the high risk of 
intubation and invasive mechanical ventilation. 
Delaying this form of treatment can be associated 
with a higher mortality. In selected patients who 
do not improve despite the properly conducted 
invasive ventilation, the use of extracorporeal 
membrane oxygenation may be considered.
The authors of this article intended to present 
the most current knowledge about the epidemi-
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ology and pathophysiology of respiratory failure 
in the course of COVID-19, as well as the meth-
ods of its treatment. Given the dynamics of the 
development of a pandemic, this is not an easy 
task as new scientific data is reported almost ev-
ery day. However, we believe that the knowledge 
contained in this review will help doctors in the 
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